Nektar Therapeutics
Nasdaq NKTR · San Francisco, CA
Works in Cardiovascular · Dermatology · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Oncology · Renal & urogenital · Respiratory · Women's health
Nektar Therapeutics is a clinical trial sponsor based in San Francisco, CA, listed as Nasdaq NKTR. It has 3 active clinical trials with 1,416 planned participants, across 13 therapeutic areas. Since 2021 it has completed 23 trials and stopped 9 early.
Trial track record · since 2021
Financials · Nasdaq NKTR
Fundraising
Pipeline · 3 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Nektar Therapeutics
Nektar Therapeutics is lead sponsor of 3 active clinical trials on ClinicalTrials.gov, with 1,416 planned participants, in Cardiovascular, Dermatology, Genetic & rare, GI & liver and other areas. Since 2021 it has completed 23 trials and stopped 9 early.
Nektar Therapeutics is based in San Francisco, CA and is listed as Nasdaq NKTR. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Nektar Therapeutics; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-16.
Approve Suite is not affiliated with Nektar Therapeutics.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.